$IMUC
EOM Pharmaceutical Holdings, Inc.

2017 Q2 Form 10-Q Financial Statement

#000162828017005577 Filed on May 15, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $988.3K $790.0K $1.100M
YoY Change -5.88% -28.18% 0.0%
% of Gross Profit
Research & Development $10.35M $4.686M $4.738M
YoY Change 133.55% -1.09% 129.4%
% of Gross Profit
Depreciation & Amortization $16.60K $16.60K $20.37K
YoY Change -19.41% -18.53% 204.35%
% of Gross Profit
Operating Expenses $11.34M $5.479M $5.837M
YoY Change 106.85% -6.14% 88.24%
Operating Profit -$11.34M -$5.479M -$5.837M
YoY Change 106.85% -6.14% 88.24%
Interest Expense $430.0K $452.7K $264.8K
YoY Change 52.49% 70.93%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.052M -$5.928M -$5.633M
YoY Change -23.97% 5.23% 295.37%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.052M -$5.928M -$5.633M
YoY Change -23.97% 5.23% 295.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$11.41M -$1.670M -$2.469M
COMMON SHARES
Basic Shares Outstanding 3.464M shares 3.460M shares 91.73M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.814M $5.340M $17.51M
YoY Change -84.82% -69.5% -49.64%
Cash & Equivalents $1.814M $5.341M $17.51M
Short-Term Investments
Other Short-Term Assets $2.589M $494.2K $612.4K
YoY Change 237.54% -19.3% -61.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.403M $7.138M $19.45M
YoY Change -69.38% -63.3% -46.54%
LONG-TERM ASSETS
Property, Plant & Equipment $76.63K $93.23K $164.6K
YoY Change -46.77% -43.35% 311.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $330.9K $3.280M $5.080M
YoY Change -93.02% -35.43% 823.64%
Total Long-Term Assets $407.5K $3.369M $5.245M
YoY Change -91.66% -35.77% 774.15%
TOTAL ASSETS
Total Short-Term Assets $4.403M $7.138M $19.45M
Total Long-Term Assets $407.5K $3.369M $5.245M
Total Assets $4.811M $10.51M $24.69M
YoY Change -75.03% -57.45% -33.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.251M $914.6K $920.0K
YoY Change 499.41% -0.59% 87.76%
Accrued Expenses $3.268M $1.010M $1.136M
YoY Change 443.12% -11.11% 14.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.720M $2.159M $2.272M
YoY Change 370.24% -4.98% 52.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.86K $7.870M $5.890M
YoY Change -99.51% 33.62% 88.78%
Total Long-Term Liabilities $27.86K $7.870M $5.890M
YoY Change -99.51% 33.62% 88.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.720M $2.159M $2.272M
Total Long-Term Liabilities $27.86K $7.870M $5.890M
Total Liabilities $7.748M $10.03M $8.163M
YoY Change 4.9% 22.85% 77.07%
SHAREHOLDERS EQUITY
Retained Earnings -$105.7M -$102.0M -$79.77M
YoY Change 24.16% 27.93%
Common Stock $102.7M $102.5M $96.30M
YoY Change 5.92% 6.47% 1.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.937M $478.7K $16.53M
YoY Change
Total Liabilities & Shareholders Equity $4.811M $10.51M $24.69M
YoY Change -75.03% -57.45% -33.23%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$4.052M -$5.928M -$5.633M
YoY Change -23.97% 5.23% 295.37%
Depreciation, Depletion And Amortization $16.60K $16.60K $20.37K
YoY Change -19.41% -18.53% 204.35%
Cash From Operating Activities -$3.453M -$6.070M -$5.351M
YoY Change -40.87% 13.45% 75.44%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $4.015K
YoY Change -100.0% 128.38%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$4.015K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -69.93K -$25.33K $264.7K
YoY Change -124.98% -109.57% -98.19%
NET CHANGE
Cash From Operating Activities -3.453M -$6.070M -$5.351M
Cash From Investing Activities $0.00 -$4.015K
Cash From Financing Activities -69.93K -$25.33K $264.7K
Net Change In Cash -3.523M -$6.096M -$5.090M
YoY Change -36.63% 19.75% -144.07%
FREE CASH FLOW
Cash From Operating Activities -$3.453M -$6.070M -$5.351M
Capital Expenditures $0.00 $4.015K
Free Cash Flow -$6.070M -$5.355M
YoY Change 13.36% 75.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000822411
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3464175 shares
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
ImmunoCellular Therapeutics, Ltd.
CY2017Q1 dei Trading Symbol
TradingSymbol
IMUC
CY2016Q1 imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
-0.03
CY2017Q1 imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
-0.01
CY2016Q1 imuc Charge To Financing Expense
ChargeToFinancingExpense
14636 USD
CY2017Q1 imuc Charge To Financing Expense
ChargeToFinancingExpense
0 USD
CY2017Q1 imuc Clinical Sites
ClinicalSites
120 site
CY2016Q1 imuc Financing Costs Incurredbut Notyet Paid
FinancingCostsIncurredbutNotyetPaid
8593 USD
CY2017Q1 imuc Financing Costs Incurredbut Notyet Paid
FinancingCostsIncurredbutNotyetPaid
90881 USD
CY2016Q1 imuc Issuance Of Warrants And Effect Of Repricing
IssuanceOfWarrantsAndEffectOfRepricing
14636 USD
CY2017Q1 imuc Issuance Of Warrants And Effect Of Repricing
IssuanceOfWarrantsAndEffectOfRepricing
0 USD
CY2017Q1 imuc Number Of Patients Target Randomized Amount
NumberOfPatientsTargetRandomizedAmount
414 patient
CY2017Q1 imuc Number Of Patients Target Randomized Amount
NumberOfPatientsTargetRandomizedAmount
542 patient
CY2016Q1 imuc Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate
0
CY2017Q1 imuc Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate
0
CY2016Q1 imuc Warrant Liability Gain Loss Included In Earnings
WarrantLiabilityGainLossIncludedInEarnings
481011 USD
CY2017Q1 imuc Warrant Liability Gain Loss Included In Earnings
WarrantLiabilityGainLossIncludedInEarnings
102776 USD
CY2016Q1 imuc Warrants Exercised
WarrantsExercised
0 USD
CY2017Q1 imuc Warrants Exercised
WarrantsExercised
0 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1342126 USD
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
914573 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
786953 USD
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1010137 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
266203 USD
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
282798 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
102354844 USD
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
102526809 USD
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
908056 shares
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1727017 shares
CY2016Q4 us-gaap Assets
Assets
16889990 USD
CY2017Q1 us-gaap Assets
Assets
10506721 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
13414789 USD
CY2017Q1 us-gaap Assets Current
AssetsCurrent
7137827 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22604481 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17514213 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11437118 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5341433 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5090268 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6095685 USD
CY2016Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
3462617 USD
CY2017Q1 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
466111 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3444859 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3449075 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3444859 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3449075 shares
CY2017Q1 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
19500060 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
344 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
345 USD
CY2016Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
100216 USD
CY2017Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
216425 USD
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2017Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27267545 USD
CY2017Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29558960 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3090903 USD
CY2017Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2668095 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30358448 USD
CY2017Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32227055 USD
CY2016Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2017Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1955514 USD
CY2017Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1920894 USD
CY2016Q1 us-gaap Depreciation
Depreciation
20370 USD
CY2017Q1 us-gaap Depreciation
Depreciation
16595 USD
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.47
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.64
CY2016Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2016Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.37
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.32
CY2016Q1 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.00
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.07
CY2016Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2017Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1109864 USD
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
234102 USD
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P12M
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
619811 USD
CY2017Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2016Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
481011 USD
CY2017Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
102776 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1099832 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
793178 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5633345 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5824987 USD
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2017Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-249821 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-518434 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
818795 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
223184 USD
CY2016Q1 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-413402 USD
CY2017Q1 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-34620 USD
CY2016Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-575079 USD
CY2017Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-875762 USD
CY2016Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
264827 USD
CY2017Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
452659 USD
CY2016Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-185052 USD
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-297297 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Supplies
IncreaseDecreaseInPrepaidSupplies
356182 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Supplies
IncreaseDecreaseInPrepaidSupplies
-55281 USD
CY2016Q1 us-gaap Interest Expense
InterestExpense
264827 USD
CY2017Q1 us-gaap Interest Expense
InterestExpense
452659 USD
CY2016Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2017Q1 us-gaap Interest Paid
InterestPaid
0 USD
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2514 USD
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3794 USD
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
8554 USD
CY2016Q4 us-gaap Liabilities
Liabilities
10758244 USD
CY2017Q1 us-gaap Liabilities
Liabilities
10027996 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16889990 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10506721 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3238943 USD
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2158812 USD
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
6945741 USD
CY2017Q1 us-gaap Long Term Debt
LongTermDebt
7398400 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
264668 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25328 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4015 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5350921 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6070357 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-5633345 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5824987 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
5837407 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
5478898 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5837407 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5478898 USD
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
27000 USD
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
68200000 USD
CY2017Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
73900000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
791485 USD
CY2017Q1 us-gaap Other Assets Current
OtherAssetsCurrent
494188 USD
CY2016Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2017Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
25328 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4015 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1309648 USD
CY2017Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1138347 USD
CY2016Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
264668 USD
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
376026 USD
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
376026 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
109823 USD
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
93228 USD
CY2013Q2 us-gaap Rental Properties
RentalProperties
8063 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4737575 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4685720 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96223442 USD
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102048429 USD
CY2016Q1 us-gaap Revenues
Revenues
0 USD
CY2017Q1 us-gaap Revenues
Revenues
0 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
227435 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
171966 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.827
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
6250 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
162665 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
156415 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
43.11
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
43.21
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
105445 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
53.20
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
40.80
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2016Q4 us-gaap Share Price
SharePrice
2.05
CY2017Q1 us-gaap Share Price
SharePrice
3.18
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M18D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y6M11D
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2017Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
171966 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
6131746 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
478725 USD
CY2016Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.025
CY2016Q4 us-gaap Supplies
Supplies
1186186 USD
CY2017Q1 us-gaap Supplies
Supplies
1302206 USD
CY2017Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2016Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2439142 USD
CY2017Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1868607 USD
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1958775 USD
CY2016Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1492400 USD
CY2016Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
573560 USD
CY2017Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
470784 USD
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2281815 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3549514 shares
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates </font><font style="font-family:inherit;font-size:10pt;">&#8211; The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these consolidated financial statements.</font></div></div>

Files In Submission

Name View Source Status
0001628280-17-005577-index-headers.html Edgar Link pending
0001628280-17-005577-index.html Edgar Link pending
0001628280-17-005577.txt Edgar Link pending
0001628280-17-005577-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imuc-20170331.xml Edgar Link completed
imuc-20170331.xsd Edgar Link pending
imuc-20170331_cal.xml Edgar Link unprocessable
imuc-20170331_def.xml Edgar Link unprocessable
imuc-20170331_lab.xml Edgar Link unprocessable
imuc-20170331_pre.xml Edgar Link unprocessable
imuc-33117x10q.htm Edgar Link pending
imuc-33117xexhibit311.htm Edgar Link pending
imuc-33117xexhibit312.htm Edgar Link pending
imuc-33117xexhibit321.htm Edgar Link pending
imuc-33117xexhibit322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending